GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year. The U.S. pharma giant expects adjusted EPS Of $ ...

Gardasil pause to China began this month Sales of Keytruda were over $7.8 billion in Q4, compared with analyst forecast of $7.4 billion Gardasil sales were $1.55 billion, compared with analyst ...

The headwinds continue to play out despite Gardasil just last month nabbing an expanded approval in China to prevent certain HPV-related cancers and diseases in men ages 9 to 25, Merck pointed out ...

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company stated. Published first ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

compared with analysts estimates of $9.03 a share. Merck's fourth-quarter Gardasil sales of $1.55 billion missed Wall Street's estimate of around $1.8 billion, which has been pared back nearly 20% ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least ... expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 ...